English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Although procalcitonin-guided antimicrobial stewardship has had proven utility in emergency and ICU settings, it is still not widely adopted outside these areas. One limitation to a more universal uptake has been the unreliable performance in discriminating bacterial infected from uninfected individuals. Viral infections have been noted to suppress procalcitonin (PCT) levels through Interferon-gamma (IFN-G)-mediated inhibition of procalcitonin release from parenchymal cells. Unfortunately, clinical application algorithms do not assess INF-G levels at the time evaluation thus treating providers are unable to distinguish a true-negative test from a false-negative test resulting from INF-G-mediated procalcitonin suppression This undermines the performance of PCT, particularly in patients with bacterial and viral co-infections. We hypothesized that adjuvant interferon gamma testing could improve the performance of PCT. To test this hypothesis we prospectively enrolled bacteremic hospitalized patients along with culture-negative controls and then assessed the performance of PCT with adjuvant IFN-G testing. Methods 69 hospitalized patients with bacteremia and 32 culture-negative controls were enrolled. Demographic and clinical parameters were compared between groups alongside INFG and PCT levels Parametric and non-parametric statistical tests were performed where appropriate. Test performance was evaluated by constructing receiver operator curves (ROCs) for PCT, INF-G, and a combination of PCT+INF-G. Results Of 101 patients enrolled, the mean age was 49.46 ± 13.6 years with 47% being female. The following were comparative statistics between the culture-positive vs. culture-negative group: mean age 52.1 ± 15.7 vs. 46.4 ± 14.2 years, P = 0.56; WBC 11.9 ± 9.5 vs. 9.5±5.1, P = 0.170; ANC 8,466 ± 5,686 vs. 8,189 ± 4,769, P = 0.907; eGFR 73.2 ± 23 vs. 74.5 ± 26.1, P = 0.644; PCT 2.79 ± 5.87 vs. 0.71 ± 1.79, P = 0.03. Of these 57 patients had INF-G and PCT values available and their corresponding ROCs are shown in figure. Conclusion Our interim results indicate adjuvant INF-G testing may not improve the performance of procalcitonin in hospitalized bacteremic patients. The additional samples are being analyzed to confirm these findings. Disclosures All authors: No reported disclosures.

2238. Evaluation of Adjuvant Interferon-Gamma-Level Assessment to Improve the Performance of Procalcitonin Testing in Hospitalized Bacteremic Patients